Please assess the completion status of the following clinical trial:

Trial Title: Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be \>/= 18 years old and able to provide consent~* Must have diagnosis of CLL as defined by NCI criteria~* Must be previously untreated for CLL~* Must require chemotherapy~* serum creatinine \<1.8 mg/dl~* Bilirubin must be \</= 2 mg/d, unless secondary to tumor~* Must have adequate liver function (as defined as \<2x ULN, unless related to CLL)~* Performance status 0-2~* Women of child bearing age must be willing to use accepted/effective method of birth control.~Exclusion Criteria:~* Not have received prior treatment with cytotoxic chemotherapy or immunotherapy.~* Not have autoimmune hemolytic anemia or autoimmune thrombocytopenia~* Not have history of corticosteroid treatment for CLL~* Not have CNS disease~* Not have clinically significant infections~* Patients with a second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix are not eligible.~* Not have positive serology for Hepatitis B or Hepatitis C~* Not have be known to be HIV positive~* Not have New York Classification III or IV hear disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ofatumumab + bendamustine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).